{
"info": {
"nct_id": "NCT00470301",
"official_title": "A Phase I-II Study of R115777 (Tipifarnib, Zarnestra®) Plus Sequential Weekly Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide in Patients With Stage IIB-IIIC Breast Cancer",
"inclusion_criteria": "* Histologically or cytologically confirmed adenocarcinoma of the breast; clinical stage IIB, IIIA, IIIB, or IIIC disease\n* At least 1 week since prior tamoxifen or other selective estrogen receptor modulator for prevention or for other indications (e.g., osteoporosis or prior ductal carcinoma in situ)\n* HER-2/neu-negative by immunohistochemistry or fluorescence in situ hybridization (FISH)\n* Hormone receptor status:\n\n * Estrogen and/or progesterone receptor-positive* [Note: *Patients enrolled on the phase I portion of the trial may have estrogen and progesterone receptor-negative disease]\n* Normal organ function including:\n* WBC >= 3,000/mm^3\n* Absolute neutrophil count >= 1,500/mm^3\n* Platelet count >= 100,000/mm^3\n* Bilirubin normal\n* AST and ALT =< 2.5 times upper limit of normal\n* LVEF normal by echocardiogram or nuclear scan\n* Creatinine normal OR Creatinine clearance >= 60 mL/min\n* FEV1 >= 1 L* and DLCO >= 50%* [Note: *Only if baseline CT scan of chest shows parenchymal lung disease OR there is a history of chronic obstructive or other pulmonary disease]\n* No prior chemotherapy, radiotherapy, or definitive therapeutic surgery (e.g., mastectomy, lumpectomy, or axillary dissection) for this cancer but prior sentinel lymph node biopsy for this malignancy allowed\n* No prior adjuvant chemotherapy for a previous breast malignancy\n* No concurrent combination antiretroviral therapy for HIV-positive patients\n* No other concurrent investigational agents\n* No other concurrent anticancer agents or therapies\n* ECOG performance status 0-1\n* Fertile patients must use effective contraception\n\nExclusion criteria:\n\n* No other invasive malignancy within the past 5 years except curatively treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix\n* No history of allergic reactions attributed to compounds of similar chemical or biological composition to tipifarnib or other study drugs (e.g., imidazoles or quinolones)\n* No other uncontrolled illness including, but not limited to, any of the following: ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia or psychiatric illness/social situations that would preclude study compliance\n* Not pregnant or nursing\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
"exclusion_criteria": "",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"line": "* Histologically or cytologically confirmed adenocarcinoma of the breast; clinical stage IIB, IIIA, IIIB, or IIIC disease",
"criterions": [
{
"exact_snippets": "Histologically or cytologically confirmed adenocarcinoma of the breast",
"criterion": "adenocarcinoma of the breast",
"requirements": [
{
"requirement_type": "confirmation method",
"expected_value": [
"histologically",
"cytologically"
]
}
]
},
{
"exact_snippets": "clinical stage IIB, IIIA, IIIB, or IIIC disease",
"criterion": "clinical stage",
"requirements": [
{
"requirement_type": "stage",
"expected_value": [
"IIB",
"IIIA",
"IIIB",
"IIIC"
]
}
]
}
]
},
{
"line": "* At least 1 week since prior tamoxifen or other selective estrogen receptor modulator for prevention or for other indications (e.g., osteoporosis or prior ductal carcinoma in situ)",
"criterions": [
{
"exact_snippets": "At least 1 week since prior tamoxifen or other selective estrogen receptor modulator",
"criterion": "time since prior selective estrogen receptor modulator",
"requirements": [
{
"requirement_type": "time since last use",
"expected_value": {
"operator": ">=",
"value": 1,
"unit": "week"
}
}
]
}
]
},
{
"line": "* HER-2/neu-negative by immunohistochemistry or fluorescence in situ hybridization (FISH)",
"criterions": [
{
"exact_snippets": "HER-2/neu-negative by immunohistochemistry or fluorescence in situ hybridization (FISH)",
"criterion": "HER-2/neu status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "negative"
},
{
"requirement_type": "testing method",
"expected_value": [
"immunohistochemistry",
"fluorescence in situ hybridization (FISH)"
]
}
]
}
]
},
{
"line": "* Hormone receptor status:",
"criterions": [
{
"exact_snippets": "Hormone receptor status",
"criterion": "hormone receptor status",
"requirements": [
{
"requirement_type": "N/A",
"expected_value": "N/A"
}
]
}
]
},
{
"line": "* Estrogen and/or progesterone receptor-positive* [Note: *Patients enrolled on the phase I portion of the trial may have estrogen and progesterone receptor-negative disease]",
"criterions": [
{
"exact_snippets": "Estrogen and/or progesterone receptor-positive",
"criterion": "hormone receptor status",
"requirements": [
{
"requirement_type": "status",
"expected_value": [
"estrogen receptor-positive",
"progesterone receptor-positive"
]
}
]
}
]
},
{
"line": "* Normal organ function including:",
"criterions": [
{
"exact_snippets": "Normal organ function",
"criterion": "organ function",
"requirements": [
{
"requirement_type": "condition",
"expected_value": "normal"
}
]
}
]
},
{
"line": "* WBC >= 3,000/mm^3",
"criterions": [
{
"exact_snippets": "WBC >= 3,000/mm^3",
"criterion": "WBC",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": ">=",
"value": 3000,
"unit": "mm^3"
}
}
]
}
]
},
{
"line": "* Absolute neutrophil count >= 1,500/mm^3",
"criterions": [
{
"exact_snippets": "Absolute neutrophil count >= 1,500/mm^3",
"criterion": "absolute neutrophil count",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": ">=",
"value": 1500,
"unit": "mm^3"
}
}
]
}
]
},
{
"line": "* Platelet count >= 100,000/mm^3",
"criterions": [
{
"exact_snippets": "Platelet count >= 100,000/mm^3",
"criterion": "platelet count",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": ">=",
"value": 100000,
"unit": "mm^3"
}
}
]
}
]
},
{
"line": "* Bilirubin normal",
"criterions": [
{
"exact_snippets": "Bilirubin normal",
"criterion": "bilirubin level",
"requirements": [
{
"requirement_type": "level",
"expected_value": "normal"
}
]
}
]
},
{
"line": "* AST and ALT =< 2.5 times upper limit of normal",
"criterions": [
{
"exact_snippets": "AST ... =< 2.5 times upper limit of normal",
"criterion": "AST",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": "<=",
"value": 2.5,
"unit": "times upper limit of normal"
}
}
]
},
{
"exact_snippets": "ALT =< 2.5 times upper limit of normal",
"criterion": "ALT",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": "<=",
"value": 2.5,
"unit": "times upper limit of normal"
}
}
]
}
]
},
{
"line": "* LVEF normal by echocardiogram or nuclear scan",
"criterions": [
{
"exact_snippets": "LVEF normal by echocardiogram or nuclear scan",
"criterion": "LVEF",
"requirements": [
{
"requirement_type": "normality",
"expected_value": "normal"
},
{
"requirement_type": "assessment method",
"expected_value": [
"echocardiogram",
"nuclear scan"
]
}
]
}
]
},
{
"line": "* Creatinine normal OR Creatinine clearance >= 60 mL/min",
"criterions": [
{
"exact_snippets": "Creatinine normal",
"criterion": "creatinine",
"requirements": [
{
"requirement_type": "level",
"expected_value": "normal"
}
]
},
{
"exact_snippets": "Creatinine clearance >= 60 mL/min",
"criterion": "creatinine clearance",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": ">=",
"value": 60,
"unit": "mL/min"
}
}
]
}
]
},
{
"line": "* FEV1 >= 1 L* and DLCO >= 50%* [Note: *Only if baseline CT scan of chest shows parenchymal lung disease OR there is a history of chronic obstructive or other pulmonary disease]",
"criterions": [
{
"exact_snippets": "FEV1 >= 1 L",
"criterion": "FEV1",
"requirements": [
{
"requirement_type": "value",
"expected_value": {
"operator": ">=",
"value": 1,
"unit": "L"
}
}
]
},
{
"exact_snippets": "DLCO >= 50%",
"criterion": "DLCO",
"requirements": [
{
"requirement_type": "value",
"expected_value": {
"operator": ">=",
"value": 50,
"unit": "%"
}
}
]
},
{
"exact_snippets": "baseline CT scan of chest shows parenchymal lung disease",
"criterion": "parenchymal lung disease",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "history of chronic obstructive or other pulmonary disease",
"criterion": "chronic obstructive or other pulmonary disease",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
}
]
}
]
},
{
"line": "* No prior chemotherapy, radiotherapy, or definitive therapeutic surgery (e.g., mastectomy, lumpectomy, or axillary dissection) for this cancer but prior sentinel lymph node biopsy for this malignancy allowed",
"criterions": [
{
"exact_snippets": "No prior chemotherapy",
"criterion": "prior chemotherapy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "No prior ... radiotherapy",
"criterion": "prior radiotherapy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "No prior ... definitive therapeutic surgery",
"criterion": "prior definitive therapeutic surgery",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "prior sentinel lymph node biopsy for this malignancy allowed",
"criterion": "prior sentinel lymph node biopsy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* No prior adjuvant chemotherapy for a previous breast malignancy",
"criterions": [
{
"exact_snippets": "No prior adjuvant chemotherapy for a previous breast malignancy",
"criterion": "prior adjuvant chemotherapy for a previous breast malignancy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "* No concurrent combination antiretroviral therapy for HIV-positive patients",
"criterions": [
{
"exact_snippets": "No concurrent combination antiretroviral therapy for HIV-positive patients",
"criterion": "combination antiretroviral therapy",
"requirements": [
{
"requirement_type": "concurrency",
"expected_value": false
}
]
}
]
},
{
"line": "* No other concurrent investigational agents",
"criterions": [
{
"exact_snippets": "No other concurrent investigational agents",
"criterion": "concurrent investigational agents",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "* No other concurrent anticancer agents or therapies",
"criterions": [
{
"exact_snippets": "No other concurrent anticancer agents or therapies",
"criterion": "concurrent anticancer agents or therapies",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "* ECOG performance status 0-1",
"criterions": [
{
"exact_snippets": "ECOG performance status 0-1",
"criterion": "ECOG performance status",
"requirements": [
{
"requirement_type": "range",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 0,
"unit": "N/A"
},
{
"operator": "<=",
"value": 1,
"unit": "N/A"
}
]
}
}
]
}
]
},
{
"line": "* Fertile patients must use effective contraception",
"criterions": [
{
"exact_snippets": "Fertile patients",
"criterion": "fertility",
"requirements": [
{
"requirement_type": "status",
"expected_value": "fertile"
}
]
},
{
"exact_snippets": "must use effective contraception",
"criterion": "contraception use",
"requirements": [
{
"requirement_type": "necessity",
"expected_value": true
}
]
}
]
},
{
"line": "* No other invasive malignancy within the past 5 years except curatively treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix",
"criterions": [
{
"exact_snippets": "No other invasive malignancy within the past 5 years",
"criterion": "invasive malignancy",
"requirements": [
{
"requirement_type": "time since last occurrence",
"expected_value": {
"operator": "<",
"value": 5,
"unit": "years"
}
},
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "except curatively treated basal cell or squamous cell skin cancer",
"criterion": "curatively treated basal cell or squamous cell skin cancer",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "except ... carcinoma in situ of the cervix",
"criterion": "carcinoma in situ of the cervix",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* No history of allergic reactions attributed to compounds of similar chemical or biological composition to tipifarnib or other study drugs (e.g., imidazoles or quinolones)",
"criterions": [
{
"exact_snippets": "No history of allergic reactions attributed to compounds of similar chemical or biological composition to tipifarnib or other study drugs (e.g., imidazoles or quinolones)",
"criterion": "allergic reactions to compounds similar to tipifarnib or other study drugs",
"requirements": [
{
"requirement_type": "history",
"expected_value": false
}
]
}
]
},
{
"line": "* No other uncontrolled illness including, but not limited to, any of the following: ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia or psychiatric illness/social situations that would preclude study compliance",
"criterions": [
{
"exact_snippets": "uncontrolled illness ... ongoing or active infection",
"criterion": "ongoing or active infection",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "uncontrolled illness ... symptomatic congestive heart failure",
"criterion": "symptomatic congestive heart failure",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "uncontrolled illness ... unstable angina pectoris",
"criterion": "unstable angina pectoris",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "uncontrolled illness ... cardiac arrhythmia",
"criterion": "cardiac arrhythmia",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "uncontrolled illness ... psychiatric illness/social situations that would preclude study compliance",
"criterion": "psychiatric illness/social situations",
"requirements": [
{
"requirement_type": "impact on study compliance",
"expected_value": false
}
]
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [],
"miscellaneous_lines": [],
"failed_inclusion": [
{
"line": "Exclusion criteria:",
"criterions": []
},
{
"line": "* Not pregnant or nursing",
"criterions": [
{
"exact_snippets": "Not pregnant",
"criterion": "pregnancy status",
"requirements": [
{
"requirement_type": "status",
"expected_value": false
}
]
},
{
"exact_snippets": "not ... nursing",
"criterion": "nursing status",
"requirements": [
{
"requirement_type": "status",
"expected_value": false
}
]
}
]
}
],
"failed_exclusion": [],
"failed_miscellaneous": []
}